Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

Irfan A. Asangani, Vijaya L. Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke, Mathew K. Iyer, Xiaojun Jing, Yi-Mi Wu, Xuhong Cao, Zhaohui S. Qin, Shaomeng Wang, Felix Y. Feng and Arul M. Chinnaiyan ()
Additional contact information
Irfan A. Asangani: Michigan Center for Translational Pathology, University of Michigan Medical School
Vijaya L. Dommeti: Michigan Center for Translational Pathology, University of Michigan Medical School
Xiaoju Wang: Michigan Center for Translational Pathology, University of Michigan Medical School
Rohit Malik: Michigan Center for Translational Pathology, University of Michigan Medical School
Marcin Cieslik: Michigan Center for Translational Pathology, University of Michigan Medical School
Rendong Yang: Emory University
June Escara-Wilke: Michigan Center for Translational Pathology, University of Michigan Medical School
Kari Wilder-Romans: University of Michigan Medical School
Sudheer Dhanireddy: Michigan Center for Translational Pathology, University of Michigan Medical School
Carl Engelke: Michigan Center for Translational Pathology, University of Michigan Medical School
Mathew K. Iyer: Michigan Center for Translational Pathology, University of Michigan Medical School
Xiaojun Jing: Michigan Center for Translational Pathology, University of Michigan Medical School
Yi-Mi Wu: Michigan Center for Translational Pathology, University of Michigan Medical School
Xuhong Cao: Michigan Center for Translational Pathology, University of Michigan Medical School
Zhaohui S. Qin: Emory University
Shaomeng Wang: Pharmacology, and Medicinal Chemistry, University of Michigan Medical School
Felix Y. Feng: Michigan Center for Translational Pathology, University of Michigan Medical School
Arul M. Chinnaiyan: Michigan Center for Translational Pathology, University of Michigan Medical School

Nature, 2014, vol. 510, issue 7504, 278-282

Abstract: Small-molecule compounds that target the BET domain in proteins such as BRD4 have recently been identified as potential anticancer agents; here, the efficacy of the BRD4-targeting compound JQ1 is demonstrated in castration-resistant prostate cancer driven by deregulated androgen receptor action.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/nature13229 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:510:y:2014:i:7504:d:10.1038_nature13229

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13229

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().